Tourmaline Bio's drug pacibekitug reduced inflammation markers in heart disease study; company plans FDA talks for Phase 3 ...

SV Health closes $269M dementia fund, Schrödinger cuts 60 jobs, Beckley Psytech's BPL-003 shows promise in depression, and ...

FDA chief Marty Makary and new CBER Director Vinay Prasad said that future Covid-19 vaccine approvals will focus on adults ...

Under the program that was first announced by President Trump last week, the US would target prices based on benchmarks from ...

Calibrate names Rob Rebak as new CEO, replacing Rob MacNaughton, amid executive changes. CFO and Chief Clinical Officer also ...

Reperio Health adds telehealth to at-home testing, raises $14M led by Caduceus Capital Partners to expand services beyond ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the ...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with ...

Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the ...

Intellia's CRISPR therapy nexiguran ziclumeran maintained reductions in the levels of a misfolded protein in the nerves of ...

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said ...

CellCentric raises $120M Series C for p300/CBP inhibitor inobrodib in multiple myeloma, plans Phase 2/3 trial for accelerated ...